Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7184976 | 0.89 | KDM4E (0.40) | ALDH1A1KDM4EMAPTHSD17B10DPP4 | |
| SCHEMBL7182250 | 0.80 | DPP4 (0.32) | ALDH1A1KDM4EMAPTDPP4 | |
| Hydrochloric Acid SCHEMBL6184127 | 0.77 | ALDH1A1 (0.45) | ALDH1A1KDM4EMAPTHSD17B10DPP4 | |
| SCHEMBL7185634 | 0.74 | BACE1 (0.50) | MAPTDPP4 | |
| Trifluoroacetic Acid SCHEMBL6184620 | 0.72 | DPP4 (0.60) | DPP4 | |
| SCHEMBL2029800 | 0.71 | ALDH1A1 (0.76) | ALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL2034753 | 0.71 | ALDH1A1 (0.76) | ALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL3059385 | 0.71 | ALDH1A1 (0.76) | ALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL31714043 | 0.71 | ALDH1A1 (0.76) | ALDH1A1KDM4EMAPTHSD17B10 | |
| SCHEMBL5490059 | 0.71 | ALDH1A1 (0.76) | ALDH1A1KDM4EMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645995-B2 | Dipeptidyl peptidase-IV (DPP-IV); treating type II diabetes in a human; amino acid amides of 2-cyanopyrrolidine | NOVO NORDISK A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | KANSTRUP ANDERS (DK) | 2002-08-01 | — | — | US | disclosed |
| US-6380398-B2 | COMPOUNDS SUCH AS (S,S)1-(2-AMINO-3,3-DIMETHYL-BUTYRYL)-2,5-DIHYDRO-1H-PYRROLE-2 -CARBONITRILE ADMINISTERED AS ANTIDIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | NOVO NORDISK A/S (DK) | 2002-04-30 | — | — | US | disclosed |
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031780-A1 | New therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | ALDH1A1 261/4885KDM4E 1835/4885MAPT 3816/4885 |
| US-20020103384-A1 | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV | DPP4, DPP7, DPP9 | ALDH1A1 229/4885KDM4E 1582/4885MAPT 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.